U.S. markets closed

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
95.12-0.69 (-0.72%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close95.81
Open95.58
Bid95.10 x 1100
Ask95.24 x 1000
Day's Range93.45 - 96.94
52 Week Range72.14 - 136.26
Volume794,071
Avg. Volume949,327
Market Cap8.887B
Beta (5Y Monthly)1.14
PE Ratio (TTM)98.77
EPS (TTM)0.96
Earnings DateFeb 02, 2021 - Feb 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 29, 1995
1y Target Est126.43
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
40% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
    PR Newswire

    Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences:

  • Neurocrine Biosciences Announces Repurchase of Convertible Notes
    PR Newswire

    Neurocrine Biosciences Announces Repurchase of Convertible Notes

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024 Notes") to repurchase approximately $83 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of an amount of cash estimated to be the sum of (i) approximately $110 million based on the Company's November 18, 2020 closing stock price of $86.91 per share, (ii) an amount based in part on the daily volume-weighted average prices per share of the Company's common stock during a five-trading day pricing period following execution of the Agreements and (iii) accrued and unpaid interest. The 2024 Notes repurchases are expected to close on December 2, 2020, subject to customary closing conditions. Such repurchases of the 2024 Notes could affect the market price of the Company's common stock.

  • Results: Neurocrine Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
    Simply Wall St.

    Results: Neurocrine Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts

    Last week, you might have seen that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its third-quarter result to...